Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Mechanisms of Ultrasound Neuromodulation Effects in Diabetes
NCT06042517 · View on ClinicalTrials.gov ↗
Study Summary
This study aims to evaluate the effect of hepatic ultrasound treatment on changes from baseline in whole-body insulin sensitivity during a hyperinsulinemic, euglycemic clamp (HE Clamp).
Conditions Studied
Interventions
- DEVICE Ultrasound
- DIAGNOSTIC_TEST OGTT with unlabeled glucose and liver NMR
- DIAGNOSTIC_TEST OGTT with carbon-13 labeled glucose and liver NMR
- DIAGNOSTIC_TEST CGM glucose reading
- DIAGNOSTIC_TEST HEC - Hyperinsulinemic-Euglycemic-Clamp
Study Locations (1)
Connecticut
- Yale School of Medicine — New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2023-09-30 |
| Est. Completion | 2027-09-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06042517
The ClinicalTrials.gov registry entry for NCT06042517 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,283 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Insulin Sensitivity appearing as the primary indexed condition, and to 5 interventions — of which Ultrasound is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06042517 reports 1 study location spanning 1 distinct geographic area — top geographies include Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06042517 about?
NCT06042517 is a clinical study titled "Mechanisms of Ultrasound Neuromodulation Effects in Diabetes". This study aims to evaluate the effect of hepatic ultrasound treatment on changes from baseline in whole-body insulin sensitivity during a hyperinsulinemic, euglycemic clamp (HE Clamp).
What is the current status of trial NCT06042517?
This trial is currently recruiting. It is a NA study. The enrollment target is 77 participants. The study started on 2023-09-30. Estimated completion is 2027-09-30.
What conditions does trial NCT06042517 study?
This clinical trial studies the following conditions: Insulin Sensitivity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06042517?
The interventions under investigation include: Ultrasound (DEVICE), OGTT with unlabeled glucose and liver NMR (DIAGNOSTIC_TEST), OGTT with carbon-13 labeled glucose and liver NMR (DIAGNOSTIC_TEST), CGM glucose reading (DIAGNOSTIC_TEST), HEC - Hyperinsulinemic-Euglycemic-Clamp (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06042517?
This trial is sponsored by Yale University, which has 1,283 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06042517 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.